We investigated whether a,-antitrypsin (a,-AT) might protect neonatal rats from the pulmonary parenchymal and vascular effects resulting from hyperoxic exposure. Neonatal rats born into and maintained in hyperoxia (60% fraction of inspired oxygen) or room air were injected with a loading dose of a,-AT (72 m a g ) followed by 36 m a g every 72 h or with vehicle during the first 14 d of life. At the end of the experimental period, we measured body weight, lung compliance, lung volume, alveoli per mm2, and total number of alveoli and assessed right ventricular hypertrophy and vascular changes consisting of medial hypertrophy, muscular extension into peripheral, normally nonmuscular arteries, and number of peripheral arteries relative to alveoli. Our data show that a,-AT treatment prevented the reduced lung compliance observed in the untreated hyperoxia-exposed neonatal rats, as well as the right ventricular hypertrophy and the associated vascular changes of medial hypertrophy of muscular arteries and muscularization of distal arteries. Reduced lung compliance in the hyperoxic but a,-AT-untreated rats was associated with a reduction in lung elastin compared with room-air or a,-AT-treated rats. In room-air rats, a,-AT treatment increased lung compliance but also reduced the number of arteries relative to the number of alveoli, a feature that was not, however, associated with right ventricular hypertrophy. Our data suggest that supplemental a,-AT might restore the imbalance in elastolytic activity induced by hyperoxia and thereby alleviate the toxic effects on lung parenchymal and vascular development.
We investigated whether a,-antitrypsin (a,-AT) might protect neonatal rats from the pulmonary parenchymal and vascular effects resulting from hyperoxic exposure. Neonatal rats born into and maintained in hyperoxia (60% fraction of inspired oxygen) or room air were injected with a loading dose of a,-AT (72 m a g ) followed by 36 m a g every 72 h or with vehicle during the first 14 d of life. At the end of the experimental period, we measured body weight, lung compliance, lung volume, alveoli per mm2, and total number of alveoli and assessed right ventricular hypertrophy and vascular changes consisting of medial hypertrophy, muscular extension into peripheral, normally nonmuscular arteries, and number of peripheral arteries relative to alveoli. Our data show that a,-AT treatment prevented the reduced lung compliance observed in the untreated hyperoxia-exposed neonatal rats, as well as the right ventricular hypertrophy and the associated vascular changes of medial hypertrophy of muscular arteries and muscularization of distal arteries. Reduced lung compliance in the hyperoxic but a,-AT-untreated rats was associated with a reduction in lung elastin compared with room-air or a,-AT-treated rats. In room-air rats, a,-AT treatment increased lung compliance but also reduced the number of arteries relative to the number of alveoli, a feature that was not, however, associated with right ventricular hypertrophy. Our data suggest that supplemental a,-AT might restore the imbalance in elastolytic activity induced by hyperoxia and thereby alleviate the toxic effects on lung parenchymal and vascular development. (Pediatr Res 36: 763-770, 1994) Abbreviations a,-AT, a,-antitrypsin BPD, bronchopulmonary dysplasia RDS, respiratory distress syndrome FiO,, fraction of inspired oxygen BPD, the condition first described by Northway et al.
(1) in 1967, is responsible for significant morbidity and mortality in preterm infants and is currently the most common cause of chronic respiratory illness of infancy (2). The advent of surfactant therapy for RDS brought with it the hope that fewer babies would go on to develop BPD or chronic lung disease. What has happened instead is that more preterm infants are surviving the acute illness, but the effect of surfactant on the incidence of BPD has been disappointing, with an absolute reduction of only 10.9% (3). Clearly, there is more to RDS than surfactant deficiency alone. The etiology of BPD is thought to be multifactorial, the most important risk factors including degree of prematurity, severity of RDS, duration and intensity of oxygen therapy, and mechanical ventilation, as well as pulmonary air leak. Other factors thought to be contributory include fluid overload, congestive heart failure, patent ductus arteriosus, infection, low levels of endogenous antioxidant enzymes, and vitamin deficiencies (3).
It has been appreciated for more than 20 y, however, that the interaction between protease and antiprotease mechanisms in the developing lung may play a key role in the pathogenesis of RDS and BPD ( 6 1 0 ) . Merritt e t al.
(11) have shown that neutrophil elastase is elevated in the tracheal lavage fluid of infants with RDS who go on to develop BPD. Teleologically, the pulmonary antiprotease system exists to protect alveoli from proteolysis by proteases such as elastases (12). Elevated elastase activity may be related to the neutrophil influx that occurs in infants with RDS who go on to develop BPD (13, 14) .
Proteases in the pulmonary parenchyma can digest fibrillar collagen (I and 111), elastin fibers, laminin, and fibronectin. a,-AT is the major modulator of elastase activity (15) and is the only antiprotease that has been extensively studied in the preterm infant (12). Although levels of a,-AT may be normal in preterm infants, exposure to high oxygen to treat respiratory failure may result in inactivation of the methionine site of a,-AT (16). Thus, there may be a place for supplemental a,-AT in the treatment of preterm infants at risk for BPD.
In this study, we therefore investigated the efficacy of a,-AT given by infusion to prevent abnormal lung parenchymal and vascular development in rat pups subjected to elevated oxygen concentrations from birth. The features and the time course of the normal early growth and remodeling of the arteries and alveoli of the newborn rat lung have been described by Meyrick and Reid (17) . Essentially, alveolar multiplication is largely observed between 3 and 8 d of life, whereas arterial concentration, constant from birth until d 8, doubles between 8 and 11 d. Our previous studies suggest that there is an additional increase in alveolar multiplication between 5 and 7 wk of life (18). The medial wall thickness of muscular preacinar arteries doubles during the second week of life but decreases with increasing size or external diameter of the vessel. Maturation of the newborn rat lung, which includes an increase in alveolar number, pulmonary arterial size and number, and a decrease in arterial medial wall thickness, appears to depend on elastic tissue remodelling, a process which, it has been speculated, is characterized by a coordination of elastin synthesis and elastolysis (16).
Previous studies in our laboratory (18), as well as by others (19) (20) (21) (22) , have demonstrated impaired lung growth in infant rats exposed to hyperoxia in that the numbers of alveoli and arteries are significantly decreased relative to values in normoxic rats. Exposure of adult rats to hyperoxia decreases alveolar concentration and produces vascular changes similar to those observed in rat pups, i.e. muscular extension into peripheral arteries and loss of small arteries (23). This hyperoxic injury has been correlated with the appearance of increased collagen rather than elastin degradation products in bronchoalveolar lavage fluid, suggesting increased activity of collagenases rather than elastases (24) . However, what has been noted in the developing lung of hyperoxic newborn rats, as well as in infants who develop BPD, is an impairment of alveolar growth that has been linked to significant elastin remodeling (25, 26) .
Oligohydramnios and smoke inhalation are two additional experimental conditions associated with a reduction in infant rat lung elastin content and impairment of alveolar development (27, 28) . Furthermore, experimentally induced elastolytic injury of infant (29) and adult (30) rat lungs produces alveolar destruction and impairment of new growth. All these studies provide evidence that elastin synthesis and elastolysis play an important role in the development of the lung.
Therefore, we hypothesized that augmentation of the newborn rat's own elastase-inhibiting capability by administration of exogenous human a,-AT may protect the developing lung from hyperoxic injury, as well as minimize the associated vascular changes.
METHODS
Experimental design. The study design consisted of 40 Sprague-Dawley rat pups from four different litters. Ten pups were studied in each of four groups: 1) room air/ vehicle, 2) room airla,-AT, 3) hyperoxia/vehicle, and 4) hyperoxia/a,-AT. Pregnant dams were exposed to hyperoxia (60% oxygen at a flow rate of 10 Llmin) or to room air in 6-ft3 Plexiglas chambers on the day before anticipated delivery. Randomization to room-air or hyperoxia exposure was performed the day before delivery of the pups. Rat pups born in hyperoxia were continually exposed for the first 14 d of life. The oxygen (Miniox I gas analyzer, Catalyst Research, Owings Mills, MD) and carbon dioxide concentrations (Medical Gas Analyzer LB-2, Beckrnan, Schiller Park, IL) in the chambers were monitored daily. Rat pups in the litters were randomly designated either &,-AT or vehicle and then separated, and the dams were alternated between room air and hyperoxia. This was performed to prevent maternal oxygen toxicity and death. The rat pups were administered either an intraperitoneal dose of &,-AT or an equal volume of saline within 1 h of birth and then at intervals of 72 h until the completion of the study on d 14. The initial loading dose was 72 mdkg and was followed by maintenance doses of 36 mglkg. These doses were calculated using first-order elimination pharmacokinetics on the basis of extrapolation from studies in humans and animals (31-34) and our previous studies in adult rats with hypoxia-induced pulmonary hypertension (35). Our predicted endpoint was a 2-fold increase in the plasma concentration of a,-AT, given the adult rat concentration of 11 + 0.9 mg/L (34). We also anticipated a similar increase in lung levels over baseline, given the relative lung tissue concentration of 10% total injected cpm radiolabeled [ 1 2 5~] a , -~~ as documented in rabbits (33). The &,-AT used was Prolastin (Cutter Biologicals, Miles Canada, Inc., Etobicoke, Ontario, Canada, a gift of Mary Ann Lark and Stan Beck), a sterile lyophilized preparation of partially purified human a,-AT obtained from pooled plasma of normal donors (31). Using United States Pharmacopeia guidelines, all lots of Prolastin were routinely tested in eight rabbits for pyrogenicity and excluded from use if any rabbit showed an increase in temperature of 0.5"C or greater.
Rat pup growth. At the end of the experimental period, the pups were weighed. Because of concerns related to growth of the room-air rat pups treated with a,-AT, we compared growth rates in two additional groups of roomair rat pups (n = 9 in each); one group was treated with a,-AT, the other with vehicle. With respect to the two additional groups, the dams were rotated between treatment and control groups, and rat pup weights were obtained on the first day of life and every 3 d thereafter until a,-ANTITRYPSIN AND OXYGEN TOXICITY 765 d 14. In the previous study, the dams were rotated be-Alveolar number = tween oxygen and room air but not between treatment corrected alveolar concentration and control groups, so some of the a,-AT-associated x lung volume reduction in rat pup weight may have been related to 1.55 x ~ differences in the dams.
Assay for q -A T levels in rat blood. At the end of the 14-d where 1.55 is the spherical constant for an alveolus and p experimental period, all rats were killed with an overdose is the volume proportion of alveoli derived by point of sodium pentobarbital (300 mgkg), and 0.5-mL blood counting the microscopic section (42). samples were removed by direct cardiac puncture for Morphometric assessment of alveolar wall elastin on measurement of &,-AT after which the heart and lungs lungs stained by the Van Gieson method was also perwere removed. Levels of &,-AT were obtained by Laurel1 formed on three rats from each of the four groups. At a rocket assay (36), as previously described, using an an-magnification of 250x, 25 fields were selected at random tibody that only reacts with human a,-AT (37). Thus, and analyzed using an eyepiece micrometer with a pointlevels could be detected only in rats that had received the counting grid (Zeiss, Jena, Germany) (42). The proporinjections of human a,-AT. The lung distribution would tion of lung alveolar wall and alveolar duct septa1 elastin be approximately 10% of the injected dose (33). was expressed as a percentage of total point counts of
Measurement of lung compliance. Separate groups of rat alveolar duct and alveolar wall septa. lungs were then either used for lung compliance or lung Vessel morphometry. Arteries were identified on the morphometry studies. Lung compliance was measured in basis of their accompanying airways and classified aclungs from five rats from each group by performing a cordingly as preacinar, terminal bronchiolus, respiratory tracheostomy (with polyethylene tubing, PE-60) and de-bronchiolus, alveolar duct, and alveolar wall, as well as gassing the lung. A three-way stopcock was connected to muscular or nonmuscular. Using an eyepiece micromethe tracheostomy, a syringe, and an electronic trans-ter, the external diameter of each respiratory and termiducer. Air was introduced in increments of 0.2 mL to a nal bronchiolus artery was measured and the percent wall total volume of 1 mL, and the corresponding inflation thickness calculated according to the following formula:
Pressures were recorded (Gould Recorder ES 1Ooo7 (2 x wall thicknessIexternal diameter) x 100 = Gould, Inc., Cleveland, OH). Linear regression analysis was performed for the data from each animal to calculate percent wall thickness the resulting lung volume for a given Pressure7 and this Medial wall thicknesses were counted for 25 vessels at value was then corrected for body weight. the terminal bronchiolus level and for 25 vessels at the of heart and lungsfor mo?Phome@'-Cannula-respiratory bronchiolus level in three different rat pups in tion of the right pulmonary artery with polyethylene tubing each group. (PE-20) was performed through the right ventricle, and the The percentage of fully muscularized arteries at the pulmonary vasculature was perfused rapidly with either alveolar duct and at the alveolar wall level was also hot (60°C) radiopaque barium gelatin until it produced a assessed in lung sections from three different rat pups in "s~owflake" appearance on the pleural surface or7 alter-each group. We next calculated in each lung section from natively, 10% buffered formalin-A tracheostom~ was Per-three different rats in each group, in 10 different fields, formed with polyethylene tubing (PE-60), and the lungs the number of arteries per 100 alveoli. were slowly distended by hand with an intratracheal infuAnalysis of data. Data from each of the four groups were si0n of 10% buffered formalin, until the pleural surfaces compared by analysis of variance followed by Tukey7s ''wept-" The barium-perfused lungs were used to assess test to determine which specific groups were different. the vasculature, the formalin-~erfused lungs to assess the Nominal data on distal arterial muscularization were anparenchyma. After fixation7 the heart was separated from alyzed by X 2 test. Comparisons with p values less than the lungs. The right ventricular free wall was dissected free 0.05 were considered significantly different. from the left ventricle with septum and each was dried and weighed separately (38). The volumes of the right lungs
RESULTS
were measured by displacement of water (18, 39) .
Lung morphometry. A 1-cm2 block of tissue was disGrowth. There was a slight (<5%) but significant insected from the midportion of the fixed lung, and 5 -~m crease in final body weight comparing vehiclelhyperoxia sections were then cut for staining by the elastin Van with vehiclelair rat pups. A 10-15% reduction in body Gieson method. Using a microscopic grid measuring 0.2 weight was, however, observed comparing the two mm2, the number of alveoli were counted at 250x mag-a,-AT groups (room air and hyperoxia) with the two nification in 10 randomly selected fields. The mean num-vehicle groups ( p < 0.01 for both comparisons) (Fig. L4) . ber of alveoli per mm2 was determined for three rats in The latter difference may have reflected interdam varieach group. A shrinkage factor of 1.32 (18) was applied to ability, because growth curves in two additional room-air the alveolar concentration, i.e. number of alveoli/mm2, to groups of rat pups in which dams were rotated showed no calculate the absolute alveolar number based on the fol-significant influence of a,-AT treatment on weight gain by lowing formula (40, 41): d 14. There were, however, slight, albeit significant, Figure 1 . A , Graph depicting body weights at the end of the experimental period. The data show a significant increase in weight in hyperoxiakehicle rats relative to room-airlvehicle rats ( p < 0.05). There is a reduction of weights in the a,-AT groups vs the vehicle groups ( p < 0.01). Values are mean r SEM; n = 12 rats per group. B, Growth curves of two room-air rat groups show no difference comparing treatment with a,-AT or vehicle. Although there were small but significant reductions in body weight in the a,-AT group compared with the vehicle group on d 3 and 10 ( p < 0.01), weights were similar at d 14.
DAY
Values are mean r SEM; n = 9 rats per group.
decreases in weight apparent on d 3 and 10 in the a,-AT compared with the vehicle group ( p < 0.01 for each comparison) (Fig. 1B) . q -A T levels. We were able to detect human a,-AT in the plasma samples from five of 10 rats receiving this agent and in none of the rats receiving vehicle. Values were at the limit of detection of our assay and ranged from 20 to 42 mg/L. Our inability to detect human a,-AT or to detect only trace amounts after 24 h might reflect degradation after complexing with proteinases.
Lung compliance. Analysis of pressure-volume curves showed no differences among the groups at pressures lower than 4 mm Hg (0.53 kPa) and a reduction in compliance in the hyperoxialvehicle rats versus the room-air/ a,-AT group at 4 mm Hg (0.53 kPa) and relative to all other groups at pressures of 5-9 mm Hg (0.67-1.20 kPa) ( p < 0.01). It was of interest that the room-airla,-AT group had significantly greater compliance than both the hyperoxia/a,-AT and the room-airlvehicle groups at pressures from 5 to 9 mm Hg (0.67-1.20 kPa). The hyperoxial a,-AT and the room-airlvehicle groups were similar. Thus, it seems that the reduced lung compliance observed with hyperoxia is prevented by a,-AT, but treatment of room-air rats with this agent produces a lung with increased compliance (Fig. 2) .
Lung morphometry: parenchyma. The reduced lung compliance in the hyperoxialvehicle group was associated with a reduced content of elastin in the lung parenchyma relative to the room-airla,-AT group ( p < 0.05) with the room-airlvehicle and hyperoxiala,-AT groups being similar and intermediate with respect to the assessment of elastin content (Fig. 3) . Examination of the histologic sections revealed the previously described alterations in the distribution and structure of individual elastin fibers, including coarsening and tortuosity in the hyperoxialvehicle lungs (25).
There were no significant differences among the four groups in morphometric assessments of lung volumes by water displacement, in alveoli per mm2, or in total number of alveoli (Table 1) . Because the evaluations were done on three animals in each group, the trend toward a reduced number of alveoli of increased size in the a,-ATtreated room-air group may have become significant, given the power calculation of 20-30%.
Right ventricular weights. There was significant right ventricular hypertrophy as judged by the ratio of right pressure (mm Hg) Figure 2 . Graph of lung compliance assessed as pressure-volume curves corrected for body weight. 0, hyperoxia; A, room air; v, vehicle. The data show a decrease in lung compliance in the hyperoxialvehicle group relative to the room-airla,-AT group at pressures as low as 4 mm Hg (0.53 kPa) (p < 0.05) and a decrease compared with all other groups at pressures higher than 5 mm Hg (0.67 kPa) ( p < 0.01) (1 mm Hg = 0.133 kPa). An increase in compliance in the room-airla,-AT group compared with the other groups is observed at pressures of 0.67 kPa and greater ( p < 0.05). Values are mean SEM; n = 5 rats per group. ventricle to left ventricle and septum in the hyperoxial vehicle group compared with the other three groups, which were similar ( p < 0.01) (Fig. 4) . Thus, a,-AT prevented the development of right ventricular hypertrophy during exposure to hyperoxia. Morphometry of pulmonary vasculature. Structural changes in the peripheral pulmonary arteries correlated with right ventricular hypertrophy in the hyperoxial vehicle rat group. The percent wall thickness of muscular arteries at respiratory bronchiolus and terminal bronchiolus levels was increased, reflecting medial hypertrophy in the hyperoxialvehicle group compared with the other groups (p < 0.05) (Fig. 5) . hat is, i h e pups exposed to hyperoxia and treated with a,-AT were protected from developing this vascular abnormality. Furthermore, the percentage of muscularized alveolar duct and wall arteries was significantly higher in the hyperoxialvehicle group (45%) compared with the hyperoxia/a,-AT-treated (13%) or room-airlvehicle and room-airla,-AT pups (15 and 23%, respectively) ( p 5 0.02, X2). The number of arteries relative to the number of alveoli was significantly increased in the room-airlvehicle pups relative to the other three groups, with the greatest reduction (approximately 30%) in the hyperoxialvehicle group ( p < 0.05) (Fig. 6 ). This suggests that a,-AT may not completely overcome the reduction in arterial concentration ob- * Values are mean? SEM; n = 5 for lung volume and n = 3 for total number of alveoli and size of aveloi as described in Methods. served with hyperoxia; this may be related to an independent effect of this agent, because a reduction in arterial concentration is also observed in the room-airla,-AT group relative to the room-airlvehicle group. The magnitude of the reduction is, however, less than 20% and does not appear to be of hemodynamic significance, inasmuch as it is not associated with right ventricular hypertrophy.
DISCUSSION
We treated rats newly born into hyperoxia or room air with injections of a,-AT. Compared with the untreated group, the room-air controls treated with a,-AT had a reduction in arterial number relative to alveolar number that was not, however, of hemodynamic significance, at least as judged by lack of right ventricular hypertrophy. The lungs were more compliant, but morphometric assessment showed only trends toward increased elastin and a reduced number of alveoli of increased size that were not statistically significant, albeit in a small sample size. There was also a tendency toward reduced weight gain that did not seem to be a consistent feature of the a,-AT treatment. There was no influence of a,-AT on right ventricular weight or arterial muscularity in roomair animals. Rats treated with &,-AT during hyperoxia, however, did not have impaired lung compliance and reduced lung elastin, as seen in untreated hyperoxiaexposed pups, nor did they have right ventricular hypertrophy and associated vascular changes of increased muscularization of peripheral arterial and increased wall thickness of muscular arteries.
Loosli and Potter (43) characterized the elastic fiber system of the lung as the key to the determination of its architecture. According to the "fishnet" theory, the elastin in the developing lung, essentially confined to the mouths of alveoli, acts as a framework on which alveoli evolve from immature saccules (44). We speculated that the process of remodeling of alveoli might involve not only elastin synthesis but also limited elastolysis and that it might therefore be possible to augment alveolar number by changing the balance of elastases to elastase inhibitors in favor of the latter by their exogenous administration. Injury to the developing lung connective tissue, especially elastin and collagen, occurs when an imbalance exists between the production of proteases and the capacity of inhibitor proteins to neutralize them (12). Preterm infants have lower levels of serum proteins, including the antiproteinases, than term infants or adults. Neutrophils secrete a serine elastase that results in the hydrolysis of extracellular matrix components, as well as immunoglobulins, fibrinogen, and complement (47). Proteolysis is necessary for the breakdown of hyaline membranes, but the uncontrolled action of elastase will have adverse effects on lung morphogenesis (12). Desmosines, elastin degradation products, have been measured in the urine of infants with RDS. Significantly greater amounts of desmosines were found in the urine of infants exposed to FiO, greater than 60% who developed BPD than those exposed to less than 40% who did not develop BPD (48).
We chose a hyperoxic exposure of 60% in our experimental studies on the basis of evidence that this degree of hyperoxia resulted in histologic and biochemical abnormalities in the newborn rat lung with low mortality (49). In separate studies, using the Leder stain to detect neutrophils, we found no evidence of accumulation in the pup lungs at 4, 6, and 14 d of hyperoxic exposure, although an influx of neutrophils may have occurred earlier. Thus, we did not establish in the rat pup lungs the source of the hyperoxia-induced increased proteolytic (elastolytic) activity. 
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The degree of hyperoxic injury to which the pups were subjected caused reduced lung compliance, although we could detect no significant reduction in lung volume, alveolar concentration, or absolute alveolar number. Although dose relationships with oxygen effects are less than clear cut, the fact that our experiments revealed no differences in these outcome parameters is at least consistent with the findings of our earlier studies, in which we exposed rat pups beginning at 10 d to a higher FiO, (80%). This exposure did not produce a significant reduction in lung alveolar number until the sixth week of exposure (18). A concentration of 80% oxygen from birth has not resulted in poor survival of the litters (our unpublished observation).
Based on the work of Emery and Fagan (44), the appearance of increased amounts of alveolar wall elastin in the room-airla,-AT lungs suggests that, with more time, these extra elastin fibers may have formed the mouths of additional alveoli. The compliance studies did reveal a significant decrease in compliance in the hyperoxia-vehicle group, as well as an increase in compliance in the group receiving a,-AT in room air. The compliance in the hyperoxia/a,-AT group was similar to that in the room-airlvehicle group. Lung compliance did not correlate with differences in fked lung volume, perhaps owing to the relative insensitivity of the latter measurement.
Compliance may be impaired by abnormalities in the configuration and distribution of elastin fibers (25). Treatment with a,-AT may, by augmenting endogenous elastase-inhibiting capacity, protect the newborn rat lung from hyperoxia-induced increases in elastase activity and assure normal lung parenchymal development. When a,-AT is, however, given to pups breathing room air, this may inhibit the normal basal levels of elastase activity, resulting in a distribution of elastin fibers that renders the lung more compliant. It is also possible that the relative increase in compliance in the a,-AT-treated room-air and hyperoxia groups may be related to &,-AT preventing the inactivation of surfactant.
The ability of elastin fibers in a given tissue to stretch is limited by the amount of collagen in that tissue (50). Kida et al. (29) demonstrated an inverse relationship between collagen and elastin in the lungs of neonatal rat pups treated with intraperitoneal elastase. Their studies revealed increased collagen relative to elastin degradation. Compliance in their model was enhanced with elastin degradation, but this may represent a concomitant increase in the amounts and types of collagen degradation in their model of elastase-induced lung injury compared with that induced by hyperoxia.
Hyperoxia-vehicle pups compared with room-air controls had a reduction in the number of arteries relative to the number of alveoli, as we have previously observed (18) . A reduction in the number of arteries relative to the number of alveoli, although less severe, was also observed in both a,-AT-treated hyperoxia and room-air pups compared with room-air controls. This may reflect differences between litters in the timing of rapid arterial multiplication, but if treatment with a,-AT truly reduced arterial concentration, the reduction was not severe enough to result in increased pulmonary vascular resistance, at least as assessed indirectly by measurements of right ventricular hypertrophy. Moreover, if a,-AT does cause a reduction in arterial concentration, then this does not seem to be compounded by the effects of hyperoxia.
Vehicle-treated pups exposed to hyperoxia underwent vascular changes, including a significant increase in arterial wall thickness at the respiratory and terminal bronchiolar levels. This finding was not observed in pups treated with a,-AT. Moreover, peripheral extension of muscle was noted to be greatest in the hyperoxialvehicle group. The result of these vascular changes was the development of right ventricular hypertrophy in the hyperoxialvehicle group, likely a reflection of the pulmonary hypertension that also occurs as a consequence of BPD in human infants (51).
Classic a,-AT deficiency is not increased in incidence in infants developing BPD. However, reduced synthesis of a,-AT compatible with immaturity or increased inactivation of a,-AT by oxidation is known to occur (16). Dexamethasone therapy for BPD has been shown to decrease by 45% the elastase activity detected in bronchoalveolar lavage without altering a,-AT (15). Yoder et al. (52) demonstrated that dexamethasone treatment resulted in a significant decrease in the requirement for respiratory support, improved pulmonary function, and reduced pulmonary inflammation indices expressed as neutrophil counts, elastase/a,-AT, albumin, and fibronectin. This provides additional evidence implicating an imbalance between elastase and elastase inhibitors in the pathogenesis of BPD while documenting efficacy in ameliorating the course of BPD by restoring the balance through dexamethasone therapy. Alternatively, a more favorable balance may be restored by augmentation of elastase inhibitors. a,-AT, a blood-derived product, has been in use in adults with a,-AT deficiency since 1987 with encouraging preliminary results (31, 53, 54) . The same investigators have used recombinant a,-AT administered as an aerosol (55). Cystic fibrosis, a disease in which patients have normal circulating levels of a,-AT but excessive lung elastase activity, is another chronic obstructive pulmonary disorder in which aerosolized a,-AT therapy has been used (56). Augmentation therapy has thus far been shown to be safe, with only minor reactions reported. However, the long-term effects of this therapy on the course of chronic lung disease still remain to be determined.
In a review of protease-antiprotease interactions in the immature lung, Merritt and Hallman (12) stated that the therapies designed to prevent or ameliorate BPD may require that they be instituted before or soon after the induction of elastase or the inactivation of endogenous antielastase to prevent structural alteration of lung connective tissue and basement membranes. This is what we have attempted to accomplish in our experimental model.
